OverviewSuggest Edit

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

TypePublic
Founded2009
HQNorwood, US
Websitecorbuspharma.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2019)141(+84%)
Job Openings1
Revenue (FY, 2019)$36.1 M(+650%)
Share Price (Oct 2020)$1.1
Cybersecurity ratingAMore

Key People/Management at Corbus Pharmaceuticals

Yuval Cohen

Yuval Cohen

Chief Executive Officer, Director
Alan Holmer

Alan Holmer

Chairman of the Board
Avery W. Catlin

Avery W. Catlin

Director
Craig Millian

Craig Millian

Chief Commercial Officer
Barbara White

Barbara White

Chief Medical Officer and Head of Research
Sean Moran

Sean Moran

Chief Financial Officer
Show more

Corbus Pharmaceuticals Office Locations

Corbus Pharmaceuticals has an office in Norwood
Norwood, US (HQ)
500 River Ridge Dr
Show all (1)

Corbus Pharmaceuticals Financials and Metrics

Corbus Pharmaceuticals Revenue

Corbus Pharmaceuticals's revenue was reported to be $36.14 m in FY, 2019
USD

Revenue (Q2, 2020)

286.3k

Net income (Q2, 2020)

(38.1m)

EBIT (Q2, 2020)

(38.1m)

Market capitalization (16-Oct-2020)

90.7m

Closing stock price (16-Oct-2020)

1.1

Cash (30-Jun-2020)

63.5m

EV

35.8m
Corbus Pharmaceuticals's current market capitalization is $90.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

648.4k1.9m2.4m4.8m36.1m

General and administrative expense

1.4m3.6m6.5m9.0m13.0m23.6m

R&D expense

1.3m5.9m15.4m26.0m48.6m89.6m

Operating expense total

2.6m9.5m21.9m35.0m61.6m113.2m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

113.6k170.5k396.6k396.6k742.6k1.3m350.2k796.3k950.4k853.6k1.1m1.9m29.1m2.6m1.8m286.3k

General and administrative expense

365.6k811.9k969.1k790.6k1.1m1.0m1.8m2.4m1.9m2.1m3.1m3.0m3.2m6.6m5.2m5.5m7.7m7.7m

R&D expense

452.6k723.4k1.7m1.6m2.2m3.6m4.3m6.4m5.8m5.6m9.8m10.3m12.8m21.8m22.2m22.2m23.9m30.7m

Operating expense total

818.2k1.5m2.7m2.4m3.3m4.6m6.1m8.7m7.6m7.8m12.8m13.2m16.0m28.4m27.4m27.7m31.6m38.4m
USDQ3, 2014

Financial Leverage

1.1 x
Show all financial metrics

Corbus Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Corbus Pharmaceuticals Online and Social Media Presence

Embed Graph

Corbus Pharmaceuticals News and Updates

Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates

Norwood, MA, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (“ECS”), today announced a restructuring of its work…

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

Norwood, MA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from its 28-week Ph…

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Norwood, MA, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollmen…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. - CRBP

NEW YORK, March 13, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or the "Company") (NASDAQ: CRBP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ...

Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference

- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET-

Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Norwood, MA, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases through the endocannabinoid system p…
Show more

Corbus Pharmaceuticals Blogs

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Topline data on schedule for Q3 2020 Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting therapies Treatment of inflammation to reduce PEx remains a key unmet need in CF Study is funded in part by a…

Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis

Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbations Study on target for data readout in late summer 2020 Norwood, MA, June 01, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or …

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Topline data on schedule for summer 2020 Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and Japan There are no FDA-approved therapies for the overall treatment of SSc Norwood, MA, May 27, 2020 (GLOBE NEWSWIRE) --…

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activation Second abstract outlines baseline characteristics of RESOLVE-1 patients in EU Norwood, MA, May 22, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CR…

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences

Norwood, MA, May 15, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Execu…

Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates

Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1 trial of CRB-4001 remains on track to initiate in third quarter of 2020 Recent appointment of Dr. Pete Salzmann to Board of …
Show more

Corbus Pharmaceuticals Frequently Asked Questions

  • When was Corbus Pharmaceuticals founded?

    Corbus Pharmaceuticals was founded in 2009.

  • Who are Corbus Pharmaceuticals key executives?

    Corbus Pharmaceuticals's key executives are Yuval Cohen, Alan Holmer and Avery W. Catlin.

  • How many employees does Corbus Pharmaceuticals have?

    Corbus Pharmaceuticals has 141 employees.

  • What is Corbus Pharmaceuticals revenue?

    Latest Corbus Pharmaceuticals annual revenue is $36.1 m.

  • What is Corbus Pharmaceuticals revenue per employee?

    Latest Corbus Pharmaceuticals revenue per employee is $256.3 k.

  • Who are Corbus Pharmaceuticals competitors?

    Competitors of Corbus Pharmaceuticals include GSK, Dalton Pharma Services and Laurus Labs.

  • Where is Corbus Pharmaceuticals headquarters?

    Corbus Pharmaceuticals headquarters is located at 500 River Ridge Dr, Norwood.

  • Where are Corbus Pharmaceuticals offices?

    Corbus Pharmaceuticals has an office in Norwood.

  • How many offices does Corbus Pharmaceuticals have?

    Corbus Pharmaceuticals has 1 office.